Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.57 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | IAPP | P10997 | 1/20 | 0.32 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921881 | 0.78 | GABRA1 (0.85) | GABRA1GABRB2PTPN5IAPPHSPA5 | |
| SCHEMBL1551923 | 0.77 | HSPA5 (0.58) | HSPA5TSHR | |
| SCHEMBL199730 | 0.75 | GABRA1 (1.00) | GABRA1GABRB2PTPN5IAPP | |
| SCHEMBL3993187 | 0.75 | LMNA (0.37) | TSHR | |
| SCHEMBL972443 | 0.73 | TRPA1 (0.44) | HSPA5 | |
| SCHEMBL3237939 | 0.73 | TAAR1 (0.41) | TSHR | |
| SCHEMBL10773164 | 0.73 | GABRA1 (0.68) | GABRA1GABRB2 | |
| SCHEMBL12816129 | 0.72 | ALDH1A1 (0.35) | TSHR | |
| SCHEMBL7768291 | 0.72 | ESR1 (0.36) | TSHR | |
| Water SCHEMBL28947715 | 0.71 | GABRA1 (0.90) | GABRA1GABRB2PTPN5IAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010041794-A1 | Nucleotide analogs | GILEAD SCIENCES, INC. | 2001-11-15 | — | — | US | claimed |
| US-5798340-A | ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY | GILEAD SCIENCES, INC. (US) | 1998-08-25 | — | — | US | claimed |
| EP-1906971-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1809277-A2 | PHOSPHONATE DERIVATIVES OF MYCOPHENOLIC ACID | GILEAD SCIENCES, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006110157-A9 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES INC (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007014352-A2 | ANTIVIRAL PHOSPHONATE CONJUGATES FOR INHIBITION OF HIV | GILEAD SCIENCES, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2006047661-A2 | PHOSPHONATE DERIVATIVES OF MYCOPHENOLIC ACID | GILEAD SCIENCES, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041794-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | GABRA1 3741/4885GABRB2 3468/4885PTPN5 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.